L
L Watson
Researcher at University of Liverpool
Publications - 13
Citations - 535
L Watson is an academic researcher from University of Liverpool. The author has contributed to research in topics: Systemic lupus erythematosus & Lupus nephritis. The author has an hindex of 10, co-authored 13 publications receiving 460 citations. Previous affiliations of L Watson include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Disease activity, severity, and damage in the UK juvenile‐onset systemic lupus erythematosus cohort
L Watson,Valentina Leone,Clarissa Pilkington,Kjell Tullus,Satyapal Rangaraj,Janet E. McDonagh,Janet Gardner-Medwin,Nick Wilkinson,Phil Riley,Jane Tizard,Kate Armon,Manish D. Sinha,Yiannis Ioannou,Neil Archer,Kathryn Bailey,Joyce Davidson,Eileen Baildam,Gavin Cleary,Liza J McCann,Michael W. Beresford +19 more
TL;DR: The data on these patients from the UK JSLE Cohort Study indicate that severe organ involvement and significant disease activity are primary characteristics in children with juvenile SLE.
Journal ArticleDOI
Urinary monocyte chemoattractant protein 1 and alpha 1 acid glycoprotein as biomarkers of renal disease activity in juvenile-onset systemic lupus erythematosus:
L Watson,Angela Midgley,Clarissa Pilkington,Kjell Tullus,Stephen D. Marks,Rcl Holt,Caroline A. Jones,Michael W. Beresford +7 more
TL;DR: Urinary MCP1 and AGP are biomarkers of LN, providing insight into its pathophysiology, and urinary IP10 concentration was not significantly different between groups, but did strongly correlate with uMCP and uAGP levels.
Journal ArticleDOI
The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE:
L Watson,Michael W. Beresford,C. Maynes,Clarissa Pilkington,Stephen D. Marks,Y Glackin,Kjell Tullus +6 more
TL;DR: Rituximab improves disease activity in children with lupus and serious AEs are infrequent and controlled studies are required.
Journal ArticleDOI
Henoch Schonlein Purpura--A 5-year Review and Proposed Pathway
TL;DR: The Alder Hey Henoch Schonlein Purpura Pathway was developed, a revised pathway for the screening of poor renal outcome in HSP, which importantly prioritises patients according to the urine findings on day 7 and thus intensively monitors those at higher risk of developing nephritis.
Journal ArticleDOI
Children and adolescents with SLE: not just little adults:
TL;DR: The enormous psychological and social impact of the disease and its treatments upon the child or young person and their family necessitates a comprehensive, holistic, specialized multidisciplinary approach to managing JSLE.